Silexion Therapeutics Corp
SLXN· Nasdaq
SLXNSilexion Therapeutics Corp
Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001178913-26-004138
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$3.55M | -$2.50M | -$1.49M | -$1.88M |
| EPS Diluted | $5.17 | $43.19 | $197.80 | $6.54 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Silexion Therapeutics Corp · CIK 2022416 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end
